Pharmacology and neuroprotective properties of rasagiline

Journal of Neural Transmission, Supplement

Volumn , Issue 48, 1996, Pages 95-101

  Finberg, J P M ^a   Lamensdorf, I ^a   Commissiong, J W ^b   Youdim, M B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; RASAGILINE; SELEGILINE; DOPAMINE; INDAN DERIVATIVE; LEVODOPA; NERVE PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; MESENCEPHALON; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; METABOLISM; MITOCHONDRION; NERVE CELL; PRENATAL DEVELOPMENT;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DOPAMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; INDANS; LEVODOPA; MESENCEPHALON; MICRODIALYSIS; MITOCHONDRIA; MONOAMINE OXIDASE INHIBITORS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 0030300167     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7494-4_9     Document Type: Article

References (23)

1. Birkmayer W, Riederer P, Youdim MBH, Linnauer W (1975) The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B deprenil. J Neural Transm 36: 303-326
2. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988
3. Buu NT, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Biochem Pharmacol 36: 1731-1735
4. Colzi A, d'Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm [Suppl] 32: 79-84
5. Finberg JPM, Youdim MBH (1985) Modification of blood pressure and nictitating membrane response to sympathomimetic amines by selective monoamine oxidase type A and type B inhibitors. Br J Pharmacol 85: 541-546
6. Finberg JPM, Tenne M, Youdim MBH (1981a) Tyramine antagonistic properties of AGN 1135 - an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65-74
7. Finberg JPM, Tenne M, Youdim MBH (1981b) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors - the state of the art. Wiley, Chichester, pp 31-43
8. Finberg JPM, Wang J, Goldstein DS, Kopin U, Bankiewicz KS (1995) Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213-1220
9. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase type A and B. Br J Pharmacol 73: 55-64
10. Kato T, Dong B, Ishii K, Kinemuchi H (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J Neurochem 46: 1277-1282
11. Knoll J (1986) The pharmacology of (-)deprenyl. J Neural Transm [Suppl]22: 75-89
12. Knoll J (1992) (-)Deprenyl medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J Am Geriatr Soc 40: 839-847
13. Kuroki T, Tsutsumi T, Hirano M, Matsumoto T, Tatebayashi Y, Nishiyama K, Uchimura H, Shiraishi A, Nakahara T, Nakamura K (1990) Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat. Psychopharmacol 102: 5-10
14. Lees A, Kohout L, Shaw JK, Stern G, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson's disease. Lancet 2: 791-795
15. O'Carroll AM, Fowler CJ, Phillips JP, Tobia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase: specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322: 198-202
16. Otsaka S, Kobayashi Y (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13: 995-1006
17. Paterson IA, Juorio AV, Berry MD, Zhu MY (1991) Inhibition of monoamine oxidase-B by (-)deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther 258: 1019-1024
18. Riederer P, Youdim MBH (1986) Brain monoamine oxidase activity and monoamine metabolism in Parkinsonian patients treated with 1-deprenyl. J Neurochem 46: 1349-1356
19. Riederer P, Konradi C, Schay V, Kienzel E, Youdim MBH (1986) Location of MAO A and MAO B in human brain. A step in understanding the thepeutic action of 1-deprenyl. Adv Neurol 45: 111-119
20. Roy E, Bedard PJ (1993) Deprenyl increases survival of rat foetal nigral neurones in culture. Neuroreport 4: 1183-1186
21. Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31: 394-400
22. Shimoda K, Sauve Y, Marini A, Schwartz JP, Commissiong JW (1992) A high yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture. Brain Res 585: 319-331
23. Simpson LL (1978) Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol 27: 1591-1595